Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer

Table 1 Association between PRL-3 expression and clinicopathological features

Factors	Patients	PRL-3 expression		P value
		Positive (n = 127)	Negative (n = 266)
Gender
Male	194	85	109	NS
Female	99	42	57
Age (yr)
< 60	149	66	83	NS
≥ 60	144	61	83
Tumor size (cm)
≥ 5	118	63	55	0.004
< 5	175	64	111
Depth of invasion
T1	22	5	17	0.008a
T2	46	15	31	0.009b
T3	175	77	98	0.042c
T4	50	30	20
Lymph node metastasis
N0	82	30	52	< 0.0001d
N1	120	42	78
N2	51	33	18
N3	40	22	18
Distant metastasis
Present	42	21	21	NS
Absent	251	106	145
Vascular/lymphatic invasion
Present	162	89	73	< 0.0001
Absent	131	38	93
Differentiation
Poor	194	91	103	NS
Well/Moderate	99	36	63
Surgical curability
Curative	200	79	121	NS
Not curative	93	48	45
Recurrencee
Absent	177	63	114	0.002
Present	23	16	7
TNM stages
I	42	13	29	0.007f
II	52	17	35	0.008g
III	99	43	56
IV	100	54	46

NS: Not significant;

^aT1-T2 vs T3-T4;

^bT1-T3 vs T4;

^cT1 vs T2-4;

^dN0-N1 vs N2-N3;

^e200 cases received curative surgery;

^fI-II vs III-IV;

^gI-III vs IV.

Table 2 Multivariate analysis of PRL-3 expression by Cox proportional hazard model

Factors	Overall survival						Disease-free survival
	All patients (n = cases)			Curatively resected (n = 200)			Curatively resected (n = 200)
	P	Relative risk	95% CI	P	Relative risk	95% CI	P	Relative risk	95% CI
PRL-3	< 0.001	1.76	1.30-2.40	< 0.001	2.35	1.54-3.59	< 0.001	2.46	1.62-3.73
T	< 0.001	3.16	1.79-5.58	0.003	3.04	1.47-6.29	0.004	2.76	1.38-5.52
N	< 0.001	3.29	1.93-5.60	< 0.001	3.99	2.21-7.20	< 0.001	4.67	2.59-8.43
D	0.04	1.38	1.01-1.88	0.32	1.23	0.82-1.87	0.015	1.69	1.11-2.57
S	< 0.001	2.24	1.54-3.26	-	-	-	-	-	-

PRL-3 expression, positive vs negative; T: Depth of invasion, T3-4 vs T1-2; N: Lymph node metastasis, present vs absent; D: Tumor size, ≥ 5 cm vs < 5 cm; S: Surgical curability, palliative vs curative.